PlainRecalls
FDA Drug Critical Class I Terminated

Ruzurgi (amifampridine) Tablets 10 mg, packaged in 100-count bottles, Rx only, Manufactured by: Jacobus Pharmaceutical Company, Inc, P.O. Box 5290, Princeton, New Jersey 08540, NDC 49938-110-01.

Reported: October 6, 2021 Initiated: September 9, 2021 #D-0008-2022

Product Description

Ruzurgi (amifampridine) Tablets 10 mg, packaged in 100-count bottles, Rx only, Manufactured by: Jacobus Pharmaceutical Company, Inc, P.O. Box 5290, Princeton, New Jersey 08540, NDC 49938-110-01.

Reason for Recall

Microbial contamination of non-sterile products: Firm's testing found lots to exceed specification for aerobic bacteria, yeast, and mold counts.

Details

Units Affected
2,324 bottles
Distribution
Product was distributed within the USA and Canada. Control # 18038, was distributed to Canada only.
Location
Plainsboro, NJ

Frequently Asked Questions

What product was recalled?
Ruzurgi (amifampridine) Tablets 10 mg, packaged in 100-count bottles, Rx only, Manufactured by: Jacobus Pharmaceutical Company, Inc, P.O. Box 5290, Princeton, New Jersey 08540, NDC 49938-110-01.. Recalled by Jacobus Pharmaceutical Company Inc.. Units affected: 2,324 bottles.
Why was this product recalled?
Microbial contamination of non-sterile products: Firm's testing found lots to exceed specification for aerobic bacteria, yeast, and mold counts.
Which agency issued this recall?
This recall was issued by the FDA Drug on October 6, 2021. Severity: Critical. Recall number: D-0008-2022.